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Background: microRNA (miRNA)’s direct regulation on target mRNA is affected by complex factors beyond miRNA.
Therefore, at different stages during the course of carcinogenesis, miRNA may regulate different targets, which we
termed ‘miRNA’s differential regulation’. HPV-induced cervical intraepithelial neoplasia (CIN) is an important pre-cancerous
course ahead of cervical cancer formation. Currently, the molecular mechanisms of CIN progress remain poorly
understood, and it is interesting to unravel this from the perspective of miRNA differential regulation.
Results: In this study, we performed transcriptome analysis of miRNAs and mRNAs for the totally 24 cervical
samples in three stages (normal, CIN I, and CIN III) along CIN progress, and proposed the SIG++ algorithm to
detect the miRNA — mRNA pairs with significant regulation change, and further proposed the definitions of
Efficient Pair, Efficient Target, and Related Effector Biological Process, as the elemental steps to construct miRNA
differential regulatory network. Finally, for the course of disease progressing from normal stage to CIN I stage, and
for the course of disease progressing from CIN I stage to CIN III stage, miRNA differential regulatory networks were
constructed, respectively, based on two distinct strategies: one is founded on the knowledge of human GO
biological processes to detect Efficient Targets and Related Effector Biological Processes, the other is solely
founded on literature review to detect the targets closely related to cervical carcinogenesis and instructive in
revealing mechanisms that promote CIN development.
Conclusions: This study provided the conception of miRNA’s differential regulation, the algorithm for how to
identify them during disease development, and the strategy for how to construct miRNA differential regulatory
network with instructive biological meanings. The finally constructed networks provide clues for understanding
CIN progress.
Keywords: microRNA’s differential regulation, Regulatory network construction, Cervical intraepithelial neoplasiaBackground
In animal cells, microRNA (miRNA) usually targets
mRNA’s 3′ untranslated region (3′ UTR) through its
5′ seed (2 nt ~ 7 nt) pairing, resulting in mRNA
destabilization or translational repression. Based on
sequence prediction, a miRNA may have binding sites
on hundreds of mRNAs, and an mRNA’s 3′UTR may also
be bound by tens of miRNAs (miRanda [1]; miRDB [2];* Correspondence: zhangyan186168@163.com; honglu0211@yahoo.com
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unless otherwise stated.etc.). Besides, miRNA’s direct binding on target mRNA
may be affected by other complex factors [3], thus during
carcinogenesis progress, a miRNA may regulate different
target mRNAs in different stages. For instance, along
prostate cancer development, we previously identified
that miR-133b represses the cell cycle control proteins
RB1CC1 and PTPRK at the early androgen-dependent
stage [4], thus essentially promotes cell proliferation;
while another group identified miR-133b functions as
tumor repressor by targeting epidermal growth factor
receptor (EGFR) at the late androgen-independent stage
[5]. Likewise, during breast cancer development, miR-224
inhibits cell invasion at the early non-invasive stage by tar-
geting chemokine receptor CXCR4 and cell division cycles is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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miR-224 promotes tumor cell’s bone metastasis by tar-
geting phosphatidylethanolamine binding protein RKIP
[7]. Therefore, the phenomenon of miRNA regulating
different targets at different stages may be universal,
and we term it ‘microRNA’s differential regulation’.
Systematically studying this aspect during tumor for-
mation, i.e. to find miRNA’s specific targets at each
stage, is critical for integrally understanding carcino-
genesis mechanisms.
A miRNA’s regulation on an mRNA can be mainly rep-
resented by their negatively correlated co-expression,
since miRNAs usually cause target mRNA degradation via
exonucleases or P-body [8]. Currently, there are several
studies analyzing the significant change of mRNA —
mRNA co-expression during cancer progress [9,10], which
partially reflects the change of protein — protein inter-
action. To our knowledge, to date there is no report
for systematically studying the significant change of
miRNA — mRNA co-expression along disease develop-
ment, as well as how to precisely determine the cellular
processes influenced by miRNA’s differential regulation.
Cervical cancer is one of the most lethal gynecologic
malignancy, and is prevalently caused by human papil-
lomavirus (HPV) infection. HPV intrudes into cervix
through tiny wound and infects the basal cells in epi-
thelium. In most cases the infection is cleared by the
immune system, and in some cases the infection per-
sists and leads the mild cervical lesions to progress
through cervical intraepithelial neoplasia (CIN). Dur-
ing CIN progress, CIN I, CIN II, and CIN III are the
early, middle, and late stages, respectively, referring to
the lesions happened in the lower third of, two-thirds
of, and more than two-thirds of epithelium, respect-
ively. After CIN III stage, malignant cells invade into
the pelvic cavity, thus cervical cancer forms. In the
field of genome-wide research for cervical carcinogen-
esis [11-14], current works mainly focus on cervical
cancer, and analyzing the role of certain miRNA with
significant expression change between tumor and nor-
mal tissue. Since CIN is the important pre-cancerous
course with many uncertainties surrounding its natural
history, it is necessary to perform genome-wide miRNA
and mRNA expression analysis along CIN stages, and re-
veal the potential mechanisms from the new perspective
of miRNA differential regulation.
In this study, we proposed SIG++ algorithm as well as
subsequent analysis strategy, to systematically construct
miRNA differential regulation mediated networks along
CIN progress. 7 normal cervical samples (HPV-), 9 CIN
I samples (HPV+), and 8 CIN III samples (HPV+) were
conducted with miRNA and mRNA expression micro-
array analysis, respectively. The finally constructed net-
works provide mechanism clues for gradual cellulardeterioration and HPV ultimate integration during CIN
progress.
Methods
The flowchart of strategy for constructing miRNA differ-
ential regulation mediated networks in this study is pre-
sented in Figure 1. The involved materials and methods
are described stepwise in the following.
Ethics statement
At the first diagnosis, patients provided written consent
that their cervical tissue samples could be used for in-
vestigational purposes. Institutional approval from local
research ethical committee was obtained for the conduct
of the study (Department of Gynaecology and Obstetrics
in Changhai Hospital, Shanghai). Samples were analyzed
anonymously.
Clinical samples
This is Step 1 in the flowchart (Figure 1). Each cervical
sample was obtained from a different patient in the
Gynaecology and Obstetrics Department of Changhai
Hospital, and was partitioned into two sections in-
stantly: one put into liquid nitrogen for research use,
the other subsequently analyzed with histopathological
CIN grading and HPV testing. Normal cervical sample
refers to the tissue adjacent to early lesions and with
no HPV detection. Then for each sample, its total RNA
was extracted and purified using the RNeasy Mini Kit
(Qiagen, Inc., Valencia, California). Only when its RNA
quality met the criteria for microarray analysis, the
sample was selected for research. Thus after careful speci-
men collection, 7 normal cervical samples (HPV-), 9 CIN
I samples (HPV+), and 8 CIN III samples (HPV+) were
used for microarray analysis.
Genome-wide expression profile by Illumina BeadArray
This is Step 2 in the flowchart (Figure 1). Total RNAs in
each sample were hybridized to Illumina HumanHT-
12 V4.0 expression beadchip (for mRNA) and Illumina
Human v2 MicroRNA expression beadchip (for miRNA)
separately. The raw data were uploaded to the Gene Ex-
pression Omnibus public repository (http://www.ncbi.
nlm.nih.gov/geo/; Gene Expression Omnibus series no.
GSE51993).
Data pre-processing
This is Step 3 in the flowchart (Figure 1). For microarray
data of miRNA and mRNA expressions, we used cubic
spline method for normalization, respectively. Then we
used previous method to amend the unauthentic data
[4]. Next, we performed gene filtering, based on the
abundance of unauthentic data. For a gene, we set the
number of its unauthentic data in normal, CIN I, and
Figure 1 Flowchart of strategy. This is the outline for analysing microarray data to construct miRNAs’ differential regulation network in this
study. Detailed steps are provided in the method and result sections.
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array data were partitioned into two parts: normal vs. CIN
I, and CIN I vs. CIN III. For the data of normal vs. CIN I, a
gene was excluded if nN ≥ 3 or nI ≥ 4; for the data of CIN I
vs. CIN III, a gene was excluded if nI ≥ 4 or nIII ≥ 4. After-
wards, the whole data were regarded as credible.Prediction of miRNA’s target mRNA based on sequence
Before identifying the miRNA — mRNA pairs with signifi-
cant regulation change, we first obtain the information of
miRNAs’ potential target mRNAs based on in silico se-
quence prediction. The miRDB database [2] and miRanda
database [1] were used for miRNA target prediction in this
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miRDB version 4.0 database, in which all targets were pre-
dicted by a tool MirTarget2, which was developed with an
SVM learning machine. Also, the targets of conserved hu-
man miRNAs with good mirSVR score were downloaded
from miRanda August 2010 release. Then for a miRNA,
the targets both predicted by the databases of miRDB and
miRanda, were used for analyzing differential regulation in
this study.
SIG++ algorithm for identifying miRNA — mRNA pair
with significant regulation change during CIN progress
This is Step 4 in the flowchart (Figure 1). miRNA’s regula-
tion on target mRNA can be mainly represented by the
Pearson correlation coefficient r [8]. If r < 0, it is regarded
that miRNA has regulation on mRNA. During disease pro-
gress from the earlier stage (e.g. normal stage) to the later
stage (e.g. CIN I stage), for a miRNA — mRNA pair, if miR-
NA’s regulation on mRNA exists in normal but does not
exist in CIN I, or does not exist in normal but exists in CIN
I, it is termed ‘regulation change’ or ‘differential regulation’.
In order to find the predicted miRNA — mRNA pairs
with significant regulation change, based on the SIG
(Stochastic process model for Identifying differentially
co-expressed Gene pair) algorithm [10], we present the
SIG++ algorithm in this study as follows. For a miRNA,
we calculate the Pearson correlation coefficient r of this
miRNA with its predicted target mRNA at one stage.
Then transform r into a metric z using Fisher’s r-to-z
transformation as z = ln[(1 + r)/(1 - r)]/2. The z-trans-
formed correlation coefficient is labeled as z-CC, which is
normally distributed. For a miRNA, let X and Y denote
the cohort of z-CCs for all predicted miRNA — mRNA
pairs at two stages, respectively, with both X and Y nor-
mally distributed:


















where x and y are the values of X and Y, while μX, μY, σX,
σY are the expectations and standard deviations, calcu-
lated according to clinical data.
Let T = X/Y, describing the co-expression change of a
miRNA — mRNA pair. Its analytical distribution is:
f T tð Þ ¼
Z ∞
−∞




f XY ty; yð Þydy−
Z 0
−∞
f XY ty; yð Þydy;
where fXY(x,y) is the joint probability density of X and Y.
z-CC started from the initial value at earlier stage andtransformed to the finial value at later stage as disease
progressed, indicating a causal association between initial
and final values. Therefore, fXY(x,y) should be calculated
by the conditional probability, which measures the prob-
ability for a variable developing to a certain final value
when its initial value is given. There are two cases in the
derivation of fT(t) based on the arrangements of X and Y.
1) X is the z-CC at later stage, and Y is the z-CC at
earlier stage,
f XY x; yð Þ ¼ G x yÞf Y yð Þ;

where G(x│y) is the conditional probability density
for z-CC transforming from y into x. G(x│y)can be
approximated using the solution of random walk
model below.
A random walk is a mathematical formalization of
a path that consists of a succession of random
steps [15]. Academically speaking, ‘random walk’
usually refers to the simple symmetric random
walk on a locally finite lattice, with the same
probabilities of the location jumping to each one
of its immediate neighbours. In this study, the
one-dimensional simple symmetric random walk
model is used, and referred as ‘random walk
model’ for simplicity. The random walk model
can be illustrated by an elementary example for a
particle: starts at 0 and at each step (the time
interval between two steps is Δτ) it moves Δx
or –Δx with equal probability, the probability of
its being at position x after time τ is modeled as
follows:ω x; τð Þ ¼ 1
2
ω x−Δx; τ−Δτð Þ þ 1
2
ω xþ Δx; τ−Δτð Þ;
where ω x; τð Þ is the probability of the particle at x
when the time point is τ. The solution of the above







where u is the probability density as u ¼ ω=2Δx,
and D is a constant as D = limΔx→ 0,Δτ→ 0 (Δx)
2/2Δx.
That solution represents the probability of a variable
under cumulative effect of many random events
over the time interval τ to reach a final value when
its initial value has been known. Based on this
central idea, the random walk model is reminiscent
of the conditional probability, since the cellular
status during tumor formation can be regarded as
Mo et al. BMC Systems Biology  (2015) 9:4 Page 5 of 17varying randomly at each step along disease





















; ⋅⋅b ¼ − μY
σ2Y





Z 0  	
and the integration A ¼
b=2a
exp −ay2 dy can be
calculated by numerical integration. K is a
normalization constant. d and D are constants and
in general let d =D = 1.
2) X is the z-CC at earlier stage, and Y is the z-CC at
later stage,
f XY x; yð Þ ¼ G y xÞf X xð Þ:

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and the integration A‘ ¼
b=2a
exp −a’y2 dy. K’ is a
normalization constant, and d =D = 1.
For a miRNA, based on its analytical distribution fT(t)
(see Additional file 1, the diagrammatic sketch), we can
detect which target mRNAs have significant regulation
change with it during disease progress. Set the threshold
value α for significance as 0.05. For a miRNA —
mRNA pair, if its clinical ratio value t* lies in the
shadow region (see Additional file 1), i.e. p < 0.05, this
pair is regarded with significant regulation change.
The procedure of SIG++ algorithm is summarized in
the following. For a miRNA, we first identify the
miRNA — mRNA pairs with regulation nonexistent
in earlier stage (stage 1) and existent in later stage
(stage 2):
a) According to Equation (1), numerically calculate
the theoretical co-expression change distribution
fT(t) for this miRNA based on it all predicted
target mRNAs.b) Calculate the Pearson coefficients r1 and r2 of this
miRNA with a target mRNA at stage 1 and stage
2, respectively. Note that noise is treated here:
if −0.2 < r < 0, it accounts for little correlation, the
sign is caused by noise, thus let r = |r|. Then
perform z-transformation, and calculate the ratio
t* = z2/z1. Finally based on fT(t), calculate the p
value. If p < 0.05, this pair is recognized with little
regulation at stage 1, and strong regulation at
stage 2.
To obtain the miRNA — mRNA pairs with
regulation existent at stage 1, and nonexistent at
stage 2, we repeat the above steps a ~ b. Note that
now in step a, fT(t) is calculated based on
Equation (2), and in step b, the ratio t* = z1/z2.
For the normal, CIN I, and CIN III stages, we
repeat the above procedure, then obtain the
whole repertoire of miRNA — mRNA pairs with
significant regulation change between adjacent
stages.Permutation method for identifying miRNA — mRNA pair
with significant regulation change during CIN progress
For comparing the results obtained by the SIG++ algo-
rithm, we also used the permutation method, which is
the traditional statistic method to assess the significance
p value, to identify miRNA — mRNA pairs with signifi-
cant regulation change between two stages. The proced-
ure is carried out as follows. In each permutation,
randomly pick up a miRNA and an mRNA (regardless of
sequence prediction), mix their expression data in two
stages, and then randomly distribute the mixed data into
two stages for miRNA and mRNA, respectively. After
that, calculate the co-expression ratio value t for this
pair. Perform such permutation 106 times to obtain the
background distribution for measuring the significance
of clinical miRNA — mRNA regulation change.
The p value for a clinically calculated value t* is esti-
mated in the following. Sort the 106 permutated t values
in ascending order. If t* < 0, then




if t* > 0, then




where n{t < t*} and n{t > t*} denote the number of t
values less than t*and larger than t*, respectively.
If p < 0.05, then the corresponding miRNA — mRNA
pair is considered with significant regulation change.
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This is Step 5 in the flowchart (Figure 1). Among the
predicted miRNA — mRNA pairs with significant regu-
lation change identified either by the SIG++ algorithm
or by the Permutation method, we further proposed the
criterion of ‘Efficient miRNA — mRNA differential
regulation Pair’, or simply termed ‘Efficient Pair’, to select
the pairs with moderate reliability for subsequent analysis.
The definition of ‘Efficient Pair’ is based on the accord-
ance between pair’s regulation change and expression
change, described as follows. In this study, for a miRNA
or an mRNA, the obvious expression change (upregulated





where āE and āL are the average expression value of this
gene in earlier and later stages, respectively. As listed in
Table 1, for a miRNA — mRNA pair, we defined the
agreement or disagreement between its regulation change
and expression change, and correspondingly defined
‘Agreement Pair’ (AP) and ‘Typical Pair’ (TP). AP and
TP are collectively termed ‘Efficient Pair’ (EP). For a
pair detected as EP, it is regarded that its regulation
change and expression change are in accordance, thus
this pair has moderate reliability prepared for the sub-
sequent network construction.
Pathway enrichment of efficient pairs
To analyze the pathway enrichment of efficient pairs, or
more precisely speaking, to analyze the pathway enrich-
ment of targets involved in the efficient miRNA — mRNA
pairs, we used the MAS system provided by CapitalBio
company, which is a freely available website (Molecule
Annotation System, http://bioinfo.capitalbio.com/mas3/),
and the output results are considerably reliable since it
covers all the knowledge of Gene Ontology (GO), KEGG,
GenMapp, and Biocarta during calculation.Table 1 Definition of the accordance between regulation cha
Regulation in stage 1 Regulation in stage 2 miRNA change
Exist Not exist ↘
Exist Not exist ↗
Exist Not exist -
Not exist Exist ↗
Not exist Exist ↘
Not exist Exist -
In this table, for a miRNA — mRNA pair, its regulation change, miRNA expression chan
(later stage) are listed, thereupon the accordance between regulation change and exp
change of miRNA or mRNA; ‘↗’ or ‘↘’ : the expression was upregulated or downregulat
between two stages. ’Agreement’ or ‘Disagreement’: for a miRNA — mRNA pair, its reg
‘Agreement Pair’ (AP) and ‘Typical Pair’ (TP) are collectively termed ‘Efficient Pair’ (EP).Identification of efficient target & related effector
biological process
For the above detected efficient pairs, we further attempt
to identify the ‘Efficient Target’ whose contribution to a
certain GO biological process is altered according to
miRNAs’ differential regulation, thus mediating miRNA’s
differential regulation to the effector process. In this
study, for an mRNA gene i involved in a GO biological
process k, its contribution to this GO process is mea-






where Nk is the total number of genes in process k, rij is
the Pearson correlation coefficient for the expressions of
gene i and gene j. eik, the average of correlation coefficients
of gene i with other genes in process k, can concisely mani-
fest gene i’s involvement in this process. The larger the eik,
the stronger contribution of gene i on GO process k.
To estimate the significance p value of an Efficient
Score, we performed 105 permutations. In each permu-
tation, mix the samples in normal, CIN I and CIN III
stages, then randomly select 10 samples, as well as ran-
domly select 10 genes which are assumed to form a ficti-
tious GO process, and calculate the Efficient Score value
e of an arbitrary gene in the fictitious process. After that,
obtain 105 permutated Efficient Scores, which work as
the background distribution to assess the p value of an
Efficient Score e* calculated by clinical data. The signifi-
cance p value is estimated as




where n{e > e*} denotes the number of permutated Effi-
cient Scores larger than e*. For an eik, if p < 0.05, then
gene i is regarded as having significant contribution to
the GO process k; else, no contribution to the process.
Combining the knowledge of efficient pair and effi-
cient score, we select the Efficient Target as well as thenge and expression change for a miRNA — mRNA pair
mRNA change Relationship definition Pair definition
↗ Agreement Agreement Pair (AP)
↘ Disagreement —
↗ — Typical Pair (TP)
↘ Agreement Agreement Pair (AP)
↗ Disagreement —
↘ — Typical Pair (TP)
ge and mRNA expression change between stage 1 (earlier stage) and stage 2
ression change is defined. ‘miRNA change’ or ‘mRNA change’: the expression
ed in stage 2 compared with stage 1; ‘-’: the expression has no obvious change
ulation change and expression change is in agreement or in disagreement. The
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present the significant downstream effect on cellular
process that was mainly caused by miRNA’s differential
regulation. The definition of Efficient Target and Related
Effector Process is depicted in Table 2, based on the ac-
cordance of miRNA regulation change and mRNA con-
tribution change. In other words, for an Efficient Pair, if
the target has contribution to a biological process when
it is not regulated by the miRNA, meanwhile the target
has no contribution to the process when it is repressed
by the miRNA, this target gene is termed ‘Efficient Target’,
and the corresponding GO process is termed ‘Related Ef-
fector Biological Process’. Since the Efficient Target medi-
ates miRNA’s differential regulation to the Related Effector
Process, the miRNA differential regulatory network can
be finally constructed, manifested by the streams of
‘miRNA→mRNA→ cellular biological process’.
In this study, all the Homo sapiens GO biological
processes with involved genes were downloaded from
Amigo2 website (http://amigo.geneontology.org/amigo).
There are totally 9,710 Human GO processes. Note that
the GO biological process containing at least 2 pre-
processed microarray genes and at least one gene involved
in the Efficient Pair, is used for Efficient Score calculation.
Construction of miRNA differential regulatory network
Founded on the detected Efficient Pairs in Step 5
(Figure 1), we used two distinct strategies to construct
miRNA differential regulatory networks. One (Step 6) is
based on known GO biological processes, through identi-
fying Efficient Target & Related Effector Process; the other
(Step 7) is solely based on literature review, including the
latest reports closely related to cervical carcinogenesis, to
detect the target genes with potential key roles in promot-
ing CIN progress.
Results and discussion
SIG++ algorithm identifies miRNA — mRNA pairs with
differential regulation during CIN progress
We performed miRNA and mRNA expression micro-
array analysis for 7 normal cervical samples (HPV-), 9
CIN I samples (HPV+), and 8 CIN III samples (HPV+),






to a process in stage 1
Exist Not exist Not exist
Not exist Exist Exist
In this table, for an already detected Efficient Pair, we further analyze the accordanc
mentioned in context, the target’s contribution to a biological process is measured
contribution to the process is regarded as ‘exist’; elsewise, as ‘not exist’. For an Effic
contribution to the process does not exist; and in the other stage, miRNA’s repressi
this target mRNA is defined as ‘Efficient Target’, and the corresponding process is d
significantly influenced by miRNA’s differential regulation, through the Efficient Targ13102 mRNAs remained for the progress from normal
to CIN I, 629 miRNAs and 13419 mRNAs remained for
the progress from CIN I to CIN III. We obtained all pre-
dicted miRNA — mRNA pairs by combining miRDB
and miRanda databases. Next, we applied the SIG++
method and permutation method to the microarray data,
respectively, and detected the miRNA — mRNA pairs
with significant regulation change. We compared the
two methods’ results from two aspects: one is the num-
ber of identified pairs, including the Efficient Pair, as
listed in Table 3; the other is the pathway enrichment
for Efficient Pairs, as illustrated in Figure 2.
As shown in Table 3, in comparison with the results
identified by the Permutation method, for the progress
from normal stage to CIN I stage, the SIG++ method
identified larger number of efficient miRNA — mRNA
pairs with regulation existent in normal and nonexistent
in CIN I, while identified less number of efficient pairs
with regulation nonexistent in normal and existent in
CIN I; for the progress from CIN I stage to CIN III stage,
the SIG++ method identified both larger number of the
efficient pairs, either with regulation existent in CIN I and
nonexistent in CIN III, or with regulation nonexistent in
CIN I and existent in CIN III. On the whole, the SIG++
method can detect larger amounts of Efficient Pairs and
therefore has the potential to reveal the molecular mecha-
nisms of CIN progress more comprehensively.
As illustrated in Figure 2, for both the two methods,
their identified Efficient Pairs are enriched in the pathways
highly related to CIN progress, such as cell cycle, apop-
tosis, migration, angiogenesis, and inflammation, etc. Fur-
thermore, in comparison with the Permutation method,
the Efficient Pairs detected by the SIG++ method are
much higher-enriched in the key pathways (Figure 2). The
above comparison suggest that the SIG++ algorithm may
be more competent in inferring the essential pathways sig-
nificant influenced by miRNAs’ differential regulation.
Pathway enrichment analysis of miRNA regulation existence
along CIN progress generalize the characteristics for each
stage
Based on the Efficient Pairs detected by the SIG++ algo-
rithm, we are further curious to know the characteristiccess
Target’s contribution





Exist Efficient target Related effector process
Not exist Efficient target Related effector process
e of miRNA regulation and target mRNA contribution to a process. As
by the Efficient Score, if the Efficient Score is significant (p < 0.05), the mRNA’s
ient Pair, if in one stage, miRNA’s repression on mRNA exists while mRNA’s
on on mRNA does not exist while mRNA’s contribution to the process exists,
efined as ‘Related Effector Process’. In summary, the Related Effector Process is
et mediation.
Table 3 Comparison of SIG++ method and permutation method from the number of identified miRNA— mRNA pairs




Normal vs. CIN I Regulations exist in normal & not exist in CIN I Ntotal 401 181
NAP 37 12
NTP 81 39
NEP = NAP + NTP 118(Set 1) 51
Regulations not exist in normal & exist in CIN I Ntotal 129 266
NAP 20 38
NTP 9 15
NEP = NAP + NTP 29 (Set 2) 53
CIN I vs. CIN III Regulations exist in CIN I & not exist in CIN III Ntotal 371 93
NAP 109 37
NTP 52 10
NEP = NAP + NTP 161 (Set 3) 47
Regulations not exist in CIN I & exist in CIN III Ntotal 107 65
NAP 6 3
NTP 9 6
NEP = NAP + NTP 15 (Set 4) 9
This table lists the number of miRNA — mRNA pairs with significant regulation change detected by the SIG++ method and by the Permutation method,
respectively. Ntotal: the number of detected differentially regulated miRNA — mRNA pairs whose targets have obvious expression change; NAP: the number of
Agreement Pair (AP); NTP: the number of Typical Pair (TP); NEP: the number of Efficient Pair (EP). For the Efficient Pairs detected by the SIG++ algorithm, ‘Set 1’
refers to the set of EP whose regulation exist in normal stage and not exist in CIN I stage, ‘Set 2’ refers to the set of EP with regulation nonexistent in normal and
existent in CIN I, ‘Set 3’ refers to the set of EP with regulation existent in CIN I and nonexistent in CIN III, and ‘Set 4’ refers to the set of EP with regulation
nonexistent in CIN I and existent in CIN III.
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along CIN progress. To achieve this, we analyzed the
pathway enrichment of the Efficient Pairs whose regula-
tion particularly exist in the interested stage. For the sets
of Efficient Pairs (Table 3, Set 1 ~ Set 4), there are 6
types of intersection (Figure 3, shown by Venn diagram),
which represent the miRNA — mRNA pairs with regula-
tion existent only in normal stage (Figure 3, type 2), or
CIN I stage (type 5), or CIN III stage (type 6), respect-
ively, and also represent the miRNA — mRNA pairs
with regulation existent both in normal and CIN I stages
(type 1), or both in CIN I and CIN III stages (type 4), or
both in normal and CIN III stages (type 3), respectively.
The pathway enrichment analysis of EPs in each inter-
section type illustrate that 117 pairs only have regulation
in normal stage (Figure 3, indicated in green), with tar-
gets enriched in the processes of inflammation, cell ad-
hesion, glycolysis, angiogenesis, etc.; 5 pairs only have
regulation in CIN I stage (Figure 3, orange); 14 pairs
only have regulation in CIN III stage (Figure 3, navy
blue), with targets enriched in provirus integration, cell
differentiation, cell migration, etc.; 156 pairs have regula-
tion both in normal and CIN I stages (Figure 3, light
blue), with targets enriched in inflammation, apoptosis,
Wnt signaling, angiogenesis, etc.; 1 pair has regulation
both in normal and CIN III stages (Figure 3, brown); 24pairs have regulation both in CIN I and CIN III stages
(Figure 3, purple), with targets enriched in keratinocyte
differentiation, cell proliferation, cell migration, NF-κB
signaling, etc. To sum up, for each stage, the specifically
existent miRNA — mRNA regulations are enriched in
inflammation; for normal stage, the specific miRNA
regulations are particularly enriched in sodium ion
transport and glycolysis; since CIN I stage, miRNA reg-
ulations have been highly enriched in cell migration and
differentiation; finally for CIN III stage, the specific
miRNA regulations are particularly enriched in virus
integration.
Construction of miRNA differential regulatory network
based on efficient targets
Founded on the 323 Efficient Pairs identified by the
SIG++ algorithm (Table 3, Set 1 ~ Set 4), we further
calculated the Efficient Scores for the targets involved,
and thereupon identified the Efficient Targets as well
as the Related Effector Processes (defined in the method
section), to finally construct miRNAs’ differential regula-
tory networks for the progress from normal stage to CIN I
stage, and for the progress from CIN I stage to CIN III
stage, respectively. The detailed results in this strategy
of network construction are presented stepwise in the
following.
Figure 2 Comparison of pathway enrichment for Efficient Pairs detected by the two methods. The Efficient Pairs (EPs) were identified by
the SIG++ method and by the Permutation method, respectively, and the pathway enrichment analysis for the involved targets are illustrated in
the sub-figures (a ~ d). (a) EPs with regulation existent in normal and nonexistent in CIN I; (b) EPs with regulation nonexistent in normal and
existent in CIN I; (c) EPs with regulation existent in CIN I and nonexistent in CIN III; (d) EPs with regulation nonexistent in CIN I and existent in
CIN III. In each sub-figure, Pathway Enrichment Score = −lgP, where P refers to the enrichment significance of a biological process.
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cesses provided in the Amigo2 website. For each of these
processes, we downloaded the gene names contained,
and then matched the microarray genes remained after
data pre-process in this study with the downloaded gene
names, thus obtained the information of GO biological
processes containing the pre-processed microarray genes.
After that, the GO process containing at least 2 pre-
processed microarray genes and at least one gene involved
in Efficient Pair, was used for Efficient Score calculation.
For the progress from normal stage to CIN I stage, there
were 993 GO processes remained for Efficient Score cal-
culation, and thereafter 16 Efficient Targets and 28 Related
Effector Processes were identified; for the progress fromCIN I stage to CIN III stage, 1,016 GO processes
remained for Efficient Score calculation, and 12 Efficient
Targets and 20 Related Effector Processes were identified.
Based on these results, miRNA differential regulatory net-
works systematically constituted by the streams of
‘miRNA→ Efficient Target→ Related Effector Process’
were constructed as illustrated in Figure 4 (for progress
from normal to CIN I) and Figure 5 (for progress from
CIN I to CIN III), respectively. The functional interpret-
ation of these networks are provided below.
For disease progressing from normal stage to CIN I
stage, there were totally 13 miRNAs, 16 Efficient Targets,
and 28 Related Effector Processes involved in the network
(Figure 4).
Figure 3 Pathway enrichment of specially existent miRNA — mRNA regulation for each stage along CIN progress. For the Efficient Pairs
(EPs) detected by the SIG++ method, the central part in this figure displays the particular existence of miRNA — mRNA regulations along the
stages. Each color has its own meaning exhibited visually in the figure and is correspondingly mentioned in the context, such as ‘Green’ referring
to the Efficient Pairs with miRNA regulation only existent in normal stage. The left part (i.e. Venn diagram) in this figure shows how to partition
the Efficient Pairs into 6 types. The meanings of Set 1 ~ Set 4 are described in Table 3, and their shadow sections in Venn diagram refer to the
EPs with regulation particularly existent in certain stage(s), indicated in corresponding colors. Finally, the pathway enrichment of EPs with
particularly existent regulation in certain stage(s) are also illustrated in corresponding colors.
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in normal stage but not in CIN I stage, thereby ACO2
having contribution to the GO processes of ‘tricarb-
oxylic acid cycle’ and ‘cellular metabolic process’ in CIN
I stage. In details, ACO2 encodes an enzyme that cata-
lyzes the interconversion of citrate to isocitrate via cis-
aconitate in the second step of the TCA cycle, which can
promote tumor cell growth and proliferation [16]. This
suggests that through miR-582-5p’s differential regula-
tion on ACO2, the TCA cycle may be accelerated in
CIN I stage, thus providing sufficient fuels for cell
activity.
For the efficient target GHR, miR-92b repressed it only
in CIN I stage, thus it had influence to the processes of
‘oxaloacetate metabolic process’, ‘taurine metabolic
process’, and ‘hormone-mediated signaling pathway’ only
in normal stage. In details, GHR encodes a member of
the type I cytokine receptor family. It has been reported
that taurine has repression effect on cervical cancer cellgrowth [17]. Therefore, we infer that through miR-92b’s
differential regulation on GHR, taurine metabolic
process may be enhanced in normal stage, thus arresting
cell grow in normal stage; while in CIN I, the arrest on
growth may be cancelled.
For the efficient target ALS2CL, miR-449b repressed it
only in CIN I stage, and it had influence on the ‘endosome
organization’ process only in normal stage. ALS2CL can
dominantly suppress the endosome enlargement [18].
While endosome plays an important role during endo-
cytosis, which is the main way of HPVs entering host cells
[19]. Our finding suggests that through miR-449b’s differ-
ential regulation on ALS2CL, the enlargement of endo-
some was not constrained in CIN I stage, thus promoting
HPV entrance into cells to form repeated infection.
For the efficient target ARSD, miR-485-5b repressed it
only in normal stage, and it had contribution to the
‘post-translational protein modification’ process only in
CIN I stage. ARSD encodes a member in the sulfatase
Figure 4 miRNA differential regulatory network for disease progressing from normal stage to CIN I stage. This network was constructed
based on Efficient Target and Related Effector Biological Process. Note that either for miRNA’s repression on target mRNA, or for mRNA’s
contribution to GO biological process, the black line denotes the action exists in the later stage (CIN I stage) but not in the earlier stage (normal
stage), while the grey line denotes the action exists in the earlier stage but not in the later stage. Both for miRNAs and mRNAs, the red color
denotes the expression is upregulated, and the green color denotes the expression is downregulated.
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capable of hydrolyzing sulfonates produced by the cyto-
solic sulfotransferases (SULT) [20]. It is well known that
dermatin sulfate and keratin sulfate are widely contained
in the skin, and keratin sulfate is necessary for the kera-
tocyte [21]. Our finding suggests that based on miR-485-
5b’s differential regulation on ARSD, the degradation of
keratin sulfate was enhanced in CIN I stage, thus pro-
moting keratocyte pathological transformation.
For the efficient target BICD1, miR-539 repressed it
only in normal stage, and it had contribution to the
‘intracellular mRNA localization’ process only in CIN I
stage. BICD1 has been implicated in the transport from
the Golgi apparatus to the endoplasmic reticulum. A
study to investigate the link between vacuolar traffic
and telomere length maintenance in Saccharomyces
cerevisiae suggested that vacuolar genes probably regu-
late telomere length by effects on the telomerase and
Ku pathways [22]. Based on this, a recent study also
suggested shorter telomeres is associated with signifi-
cantly lower BICD1 mRNA level in human leukocytes
[23]. Our finding suggests that elicited by miR-539’s dif-
ferential regulation on BICD1, the length of telomeres
may be prolonged in CIN I stage, thus promoting cell
immortalization transformation.For the efficient target NTRK2, miR-548-5b repressed
it only in CIN I stage, and it had contribution to the pro-
cesses of ‘positive regulation of axonogenesis’, ‘regulation
of Rac GTPase activity’, and ‘regulation of protein kinase B
signaling’ only in normal stage. NTRK2 encodes a mem-
ber of the neurotrophic tyrosine receptor kinase (NTRK)
family. It has been reported that Am80 induces neuronal
differentiation by increasing NTRK2 expression [24]. Our
finding suggests that through miR-548-5b’s differential
regulation on NTRK2, cell differentiation may be impaired
in CIN I stage, thus leading cell to the poorly differenti-
ated carcinogenesis transformation.
For the efficient target CCNE1, miR-497 repressed it
only in normal stage, and it had contribution to the
‘DNA replication initiation’ process only in CIN I stage.
CCNE1 encodes cyclin E1, which allows G1/S passage.
Our finding suggests that based on miR-497’s differential
regulation on CCNE1, the cell cycle G1/S transition may
be promoted in CIN I stage.
For the efficient target CHEK1, miR-497 repressed it
only in normal stage, and it had contribution to the
‘regulation of double-strand break repair via homologous
recombination’ process only in CIN I stage. The protein
encoded by CHEK1 belongs to the Ser/Thr protein kinase
family, and is required for checkpoint-mediated cell cycle
Figure 5 miRNA differential regulatory network for disease progressing from CIN I stage to CIN III stage. This network was also
constructed based on Efficient Target and Related Effector Biological Process. The colors have the same meaning as in Figure 4. Note that here
the earlier and later stages refer to the CIN I stage and CIN III stage, respectively.
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from ATM and ATR, to phosphorylate CDC25A protein,
thereby delaying cell cycle in response to double-strand
DNA breaks. On the other hand, it has been recently re-
ported that HPV genomes associate with BRD4 to repli-
cate at fragile sites in the host genome by utilizing host
DNA damage responses, thus greatly increasing the
chances of HPV integration [25]. Our finding suggests
that based on miR-497’s differential regulation on CHEK1,
the homologous recombination repair for DNA double-
strand break was stimulated in CIN I stage, which may en-
hance the chance of HPV integration.
For the efficient target RBM38, miR-455-3p repressed
it only in normal stage, and it had contribution to the
‘3′-UTR-mediated mRNA stabilization’ process only in
CIN I stage. The protein encoded by RBM38 is a RNA-
binding protein (RBP), and can interact with uridine-
rich regions near miRNA target sequences to block miR-
NA’s binding on target, thus protecting the expression of
genes transcribed by p53 regulation [26]. Our finding
suggests that based on miR-455-3p’s differential regula-
tion on RBM38, the response for DNA double-strand
break may be promoted in CIN I stage by carrying out
p53 downstream processes, thus may promote HPV
integration.For the efficient target COL12A1, miR-92a repressed it
only in normal stage, and it had contribution to the pro-
cesses of ‘extracellular matrix organization’, ‘extracellular
matrix disassembly’, ‘collagen catabolic process’, and ‘col-
lagen fibril organization’ only in CIN I stage. COL12A1
encodes the alpha chain of type XII collagen, which is a
homotrimer found in association with type I collagen, an
association that is thought to modify the interactions be-
tween collagen I fibrils and the surrounding matrix. Our
finding suggests that based on miR-92a’s differential
regulation on COL12A1, the interaction between cell
and surrounding matrix may be enhanced in CIN I stage
to promote cell invasion.
For the efficient target DSC2, miR-323-3p and miR-
92a repressed it only in normal stage, and it had contri-
bution to the process of ‘bundle of His cell to Purkinje
myocyte communication’ only in CIN I stage. The pro-
tein encoded by DSC2 is a calcium-dependent glyco-
protein as a member of the desmocollin family, whose
members are found primarily in epithelial cells and are
required for cell adhesion and desmosome formation
[27]. Our finding suggests that based on miRNAs’
differential regulation on DSC2, the intercellular com-
munication and cell adhesion may be enhanced in CIN
I stage.
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pressed it only in normal stage, and it had contribution
to the ‘ventricular system development’ process only in
CIN I stage. SEMA6D has been demonstrated as critic-
ally involved in cardiac morphogenesis [28]. In gastric
carcinoma, SEMA6D may play an important role in
tumor angiogenesis [29]. Our finding suggests that
induced by miR-323-3p’s differential regulation on
SEMA6D, the angiogenesis may be enhanced in CIN I
stage.
For the efficient target VCAM1, miR-941 repressed it
only in normal stage, thus it had contribution to the
‘regulation of immune response’ process only in CIN I
stage. VCAM1 encodes vascular cell adhesion molecule,
which mediates leukocyte-endothelial cell adhesion and
signal transduction in order to enhance inflammation
in cervical tissue [30]. Our finding suggests that based
on miR-941’s differential regulation on VCAM1, the
leukocyte-endothelial cell adhesion may be promoted
in CIN I stage, thus accelerating inflammation in local
tissue.
For the efficient target SLC11A2, miR-92a repressed it
only in normal stage, thus it had contribution to the
processes of ‘zinc ion transmembrane transport’, ‘cobalt
ion transport’, ‘copper ion transmembrane transport’, and
‘cadmium ion transmembrane transport’ only in CIN I
stage. SLC11A2 encodes a solute carrier protein and is
involved in iron absorption, while iron is essential for
host cell synthesis of virions [31]. Our finding suggests
that through miR-92a’s differential regulation on SLC11A2,
the ion transport in cells may be enhanced in CIN I stage,
which may promote virion synthesis.
For the efficient target SLC30A5, miR-590-3p repressed
it only in normal stage, thus it had contribution to the
processes of ‘zinc ion transmembrane transport’, ‘cellular
zinc ion homeostasis’, and ‘cobalt ion transport’ only in
CIN I stage. Similar to SLC11A2, our finding suggests that
through miR-590-3p’s differential regulation on SLC30A5,
the ion transport in cells may be enhanced in CIN I stage
to promote virion synthesis.
For disease progressing from CIN I stage to CIN III
stage, there were totally 12 miRNAs, 12 Efficient Targets,
and 20 Related Effector Processes involved in the miRNA
differential regulatory network (Figure 5).
For the efficient target AXIN2, miR-622 repressed it in
CIN I stage but not in CIN III stage, and AXIN2 having
contribution to the ‘dorsal/ventral axis specification’
process only in CIN III stage. AXIN2 encodes the Axin-
related protein, which plays an important role in the
regulation of the stability of beta-catenin in the Wnt sig-
naling, and can promote cell proliferation in ovarian
cancer [32]. Our finding suggests that due to miR-622’s
differential regulation on AXIN2, the Wnt signaling may
be stabilized in CIN III stage.For the efficient target DVL3, miR-920 repressed it
only in CIN I stage, and it had contribution to the
‘planar cell polarity pathway involved in neural tube
closure’ process only in CIN III stage. DVL3 encodes a
cytoplasmic phosphoprotein which can activate the
Wnt/β-catenin signaling in cervical cancer [33]. Our
finding suggests that miR-920’s differential regulation
on DVL3 may contribute to activating the Wnt signal-
ling in CIN III stage.
For the efficient target LEF1, miR-507 repressed it only
in CIN I stage, and it had contribution to the processes
of ‘Wnt signaling pathway’, ‘embryonic limb morphogen-
esis’, ‘positive regulation of epithelial to mesenchymal
transition’, ‘mammary gland development’, ‘tongue devel-
opment’, and ‘paraxial mesoderm formation’ only in CIN
III stage. Based on this, our finding suggests that miR-
507’s differential regulation on LEF1, may lead to cell
poor differentiation in CIN III stage.
For the efficient target FBXO5, miR-654-3p re-
pressed it only in CIN I stage, and it had contribution
to the ‘microtubule polymerization’ process only in
CIN III stage. Note that ‘microtubule polymerization’
is closely related to cell cycle. The protein encoded by
FBXO5 is a subunit of protein ligase complex, which
has anti-apoptotic and proliferative abilities in breast
carcinoma [34]. On the other hand, the high expres-
sion of FBXO5 can promote genomic instability [35].
Our finding suggests that due to miR-654-3p’s differ-
ential regulation on FBXO5, the cell proliferation as
well as genomic instability may be enhanced in CIN III
stage.
For the efficient target SH2B3, miR-940 repressed it
only in CIN I stage, and it had contribution to the ‘embry-
onic hemopoiesis’ process only in CIN III stage. Our find-
ing suggests that due to miR-940’s differential regulation
on SH2B3, the angiogenesis process may be promoted in
CIN III stage.
For the efficient target SOX18, miR-548b-5p repressed
it only in CIN I stage, and it had contribution to the
‘embryonic hemopoiesis’ process only in CIN III stage.
SOX18 has a role in cervical cancer by facilitating
angiogenesis [36]. Our finding suggests that based on
miR-548b-5p’s differential regulation on SOX18, the
angiogenesis may be enhanced in CIN III stage.
For the efficient targets CD27, TLR7 and TNFAIP3,
miR-299-3p, miR-525-5p and miR-603 repressed them
only in CIN I stage, respectively, and these targets have
contribution to the processes of ‘immunoglobulin medi-
ated immune response’, ‘release of cytoplasmic sequestered
NF-kappaB’, ‘pathogen - associated molecular pattern
dependent induction by symbiont of host innate im-
mune response’, and ‘response to molecule of bacterial
origin’ only in CIN III stage. Our findings suggest that
due to miRNAs’ differential regulation on CD27, TLR7
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greatly intensified in CIN III stage.
In summary, mainly based on observing the cervical
samples in normal stage, CIN I stage, and CIN III
stage in this study, the constructed miRNA differential
regulatory networks for the course from normal stage
to CIN I stage (Figure 4), and for the course from CIN
I stage to CIN III stage (Figure 5), respectively, com-
binatively implicate that the common characteristic
for CIN I and CIN III stages is inflammation and
angiogenesis, the specific characteristic for CIN I
stage is cell invasion and virion synthesis, and for
CIN III stage is the poor differentiation. These deriv-
ation are majorly consistent with the characteristics
previously deduced by pathway enrichment (illustrated in
Figure 3).Figure 6 miRNA particular regulatory network in normal stage. This netw
inference. The symbol annotation is provided in the lower right corner in the figConstruction of miRNA particular regulatory network at
each stage solely based on literature review
On the other aspect, GO biological processes have been
mainly summarized by manual review, which may have
neglect on comprehensiveness and update, to overcome
this, in this study we also used another way to construct
miRNA differential regulatory network, by carrying out
extensive literature review for the targets in the total 323
Efficient Pairs, to find genes closely related to cervical
carcinogenesis. After that, we finally selected 99 Efficient
Pairs, including 78 miRNAs and 69 target mRNAs.
Based on those, we systematically constructed the
miRNA particular regulatory networks for normal, CIN
I, and CIN III stages, respectively (Figures 6, 7, and 8),
displaying miRNAs’ regulation change and the possibly
induced downstream effect from the eight aspects:ork and the following two networks were constructed based on literature
ure. Note that, Purple/Blue: miRNA/mRNA expression at normal stage.
Figure 7 miRNA particular regulatory network in CIN I stage. Note that, Purple/Blue: miRNA/mRNA expression in CIN I stage has no obvious
change compared with normal stage; Light pink/Orange: miRNA/mRNA expression in CIN I stage was upregulated than in normal stage, termed
‘increased once than normal’; Mint green/Grass green: miRNA/mRNA expression in CIN I stage was downregulated than in normal stage, termed
‘decreased once than normal’.
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proliferation, invasion & migration, virus infection, cell
immortalization, and energy metabolism. See Additional
file 2 for the detailed molecular elucidation for these
networks (Figures 6, 7 and 8).
To generalize, during HPV-induced CIN progress, the
malignant development in host cells has been promoted
by multiple cooperative miRNA — mRNA regulation
changes, as represented in the networks (Figures 4, 5, 6,
7 and 8), eventually leading to cervical cancer formation.
Conclusions
In conclusion, we provided a genome-wide clinical data
concerning miRNA and mRNA expressions for the threestages in HPV-induced CIN progress (normal, CIN I, and
CIN III). By applying the proposed SIG++ algorithm, we
obtained the miRNA — mRNA pairs with significant
regulation change between two adjacent stages, and de-
tected the Efficient Pairs among them, based on which we
finally constructed the miRNA differential regulation net-
works for the CIN course, either from the perspective of
Efficient Target and Related Effector Process, or from the
perspective of sole literature review. To summarize, our
work provides an effective strategy for studying miRNAs’
differential regulation during carcinogenesis development;
also by analyzing the natural history of CIN, our work
provides several molecular clues for therapeutic interven-
tion of CIN regression.
Figure 8 miRNA particular regulatory network in CIN III stage. Note that, Light pink/Orange: miRNA/mRNA expression in CIN III stage has no obvious
change compared with CIN I stage when expression in CIN I stage was already increased, or miRNA/mRNA expression in CIN III stage was upregulated
than CIN I stage when expression in CIN I stage had no obvious change compared with normal stage, termed ‘increased once than normal’; Magenta/
Pure red: miRNA/mRNA expression in CIN III stage was upregulated than in CIN I stage when expression in CIN I stage was already increased, termed
‘increased twice than normal’. Likewise, the terms of ‘decreased once than normal’ and ‘decreased twice than normal’ have the analogic meanings.
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The raw microarray data provided in this study are avail-
able in the Gene Expression Omnibus public repository
(http://www.ncbi.nlm.nih.gov/geo/; Gene Expression
Omnibus series no. GSE51993).Additional files
Additional file 1: Diagrammatic sketch of the analytical distribution
function fT(t). Description: t represents the co-expression change of a
miRNA — mRNA pair between earlier stage and later stage. If the clinical
value t* locates in the shadow region (p < 0.05), the corresponding pair is
regarded as having significant regulation change between the two
stages.Additional file 2: Molecular elucidation of miRNA particular
regulatory networks constructed solely based on literature review.
This additional file provides detailed molecular elucidation for miRNA
particular regulatory networks (Figures 6, 7, and 8) constituted by the 99
Efficient Pairs selected based on extensive literature review. Through our
findings and inference, the potential molecular mechanisms for the course
of CIN deterioration are provided from eight aspects: inflammation,
angiogenesis, cellular stress, apoptosis & proliferation, invasion & migration,
virus infection, cell immortalization, and energy metabolism.
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